m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00641)
Name
Raltitrexed
Synonyms
(2S)-2-[[5-[methyl-[(2-methyl-4-oxo-1H-quinazolin-6-yl)methyl]amino]thiophene-2-carbonyl]amino]pentanedioic acid; 112887-68-0; C21H22N4O6S; CHEBI:5847; CHEMBL225071; D 1694; D-1694; D1694; DSSTox_CID_26482; DSSTox_GSID_46482; DSSTox_RID_81653; FCB9EGG971; ICI D1694; ICI-D-1694; ICI-D1694; N-(5-(N-(3,4-Dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino)-2-thenoyl)-L-glutamic acid; NCGC00229704-01; NSC-639186; Raltitrexed (Tomudex); Tomudex; UNII-FCB9EGG971; ZD 1694; ZD-16; ZD-1694; ZD1694
    Click to Show/Hide
Status
Approved
Structure
Formula
C21H22N4O6S
InChI
1S/C21H22N4O6S/c1-11-22-14-4-3-12(9-13(14)19(28)23-11)10-25(2)17-7-6-16(32-17)20(29)24-15(21(30)31)5-8-18(26)27/h3-4,6-7,9,15H,5,8,10H2,1-2H3,(H,24,29)(H,26,27)(H,30,31)(H,22,23,28)/t15-/m0/s1
InChIKey
IVTVGDXNLFLDRM-HNNXBMFYSA-N
PubChem CID
135400182
VARIDT Drug ID
DR00958
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Breast cancer resistance protein (ABCG2)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Breast cancer resistance protein (ABCG2) is a therapeutic target for Raltitrexed. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Raltitrexed through regulating the expression of Breast cancer resistance protein (ABCG2). [1], [2]
References
Ref 1 METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner. Exp Mol Med. 2021 Jan;53(1):91-102. doi: 10.1038/s12276-020-00510-w. Epub 2021 Jan 8.
Ref 2 Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9.